Journal article
Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum
Abstract
Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban and rivaroxaban reversal. Non-specific prohemostatic agents such as prothrombin complex concentrate (PCC) and activated PCC have also been used for DOAC reversal. The goal of this document is to provide comprehensive guidance from the Anticoagulation Forum, a North …
Authors
Cuker A; Burnett A; Triller D; Crowther M; Ansell J; Van Cott EM; Wirth D; Kaatz S
Journal
American Journal of Hematology, Vol. 94, No. 6, pp. 697–709
Publisher
Wiley
Publication Date
6 2019
DOI
10.1002/ajh.25475
ISSN
0361-8609